Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Humana Inc. (NYSE:HUM). In a filing disclosed on March 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Humana stock on February 26th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Purchased $1,001 – $15,000 in shares of Sterling Infrastructure (NASDAQ:STRL) on 3/3/2025.
- Purchased $1,001 – $15,000 in shares of Hillman Solutions (NASDAQ:HLMN) on 3/3/2025.
- Sold $1,001 – $15,000 in shares of Ford Motor (NYSE:F) on 2/26/2025.
- Purchased $1,001 – $15,000 in shares of Uber Technologies (NYSE:UBER) on 2/26/2025.
- Sold $15,001 – $50,000 in shares of UnitedHealth Group (NYSE:UNH) on 2/26/2025.
- Purchased $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 2/26/2025.
- Sold $1,001 – $15,000 in shares of General Motors (NYSE:GM) on 2/26/2025.
- Purchased $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 2/26/2025.
- Sold $1,001 – $15,000 in shares of Akamai Technologies (NASDAQ:AKAM) on 2/26/2025.
- Sold $1,001 – $15,000 in shares of Danaher (NYSE:DHR) on 2/26/2025.
Humana Trading Down 2.2 %
Shares of NYSE:HUM opened at $259.86 on Friday. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The company’s fifty day simple moving average is $271.80 and its 200 day simple moving average is $283.63. The firm has a market cap of $31.35 billion, a price-to-earnings ratio of 26.12, a PEG ratio of 2.05 and a beta of 0.57.
Humana Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.36%. Humana’s payout ratio is 35.58%.
Institutional Trading of Humana
Several large investors have recently made changes to their positions in HUM. Creative Financial Designs Inc. ADV raised its stake in shares of Humana by 244.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after acquiring an additional 61 shares during the last quarter. Ashton Thomas Securities LLC bought a new position in shares of Humana during the third quarter valued at $31,000. FPC Investment Advisory Inc. bought a new position in shares of Humana during the fourth quarter valued at $27,000. Centricity Wealth Management LLC bought a new position in shares of Humana during the fourth quarter valued at $30,000. Finally, LFA Lugano Financial Advisors SA raised its stake in shares of Humana by 56.3% during the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 45 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.
Analysts Set New Price Targets
Several equities research analysts have commented on the stock. StockNews.com cut shares of Humana from a “buy” rating to a “hold” rating in a research report on Wednesday. Cantor Fitzgerald reissued a “neutral” rating and set a $290.00 price target on shares of Humana in a research report on Wednesday, February 12th. Royal Bank of Canada reissued an “outperform” rating and set a $283.00 price target on shares of Humana in a research report on Wednesday, February 12th. Morgan Stanley cut their price target on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 12th. Finally, Barclays boosted their price target on shares of Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. Twenty equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Humana presently has an average rating of “Hold” and an average target price of $285.68.
Read Our Latest Analysis on HUM
Insider Activity
In other news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.32% of the company’s stock.
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
About Humana
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Recommended Stories
- Five stocks we like better than Humana
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- 3 Stocks to Buy While Others Stay on the Sidelines
- Short Selling – The Pros and Cons
- MarketBeat Week in Review – 03/03 – 03/07
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.